Search

Your search keyword '"Touchefeu, Yann"' showing total 302 results
Start Over Author "Touchefeu, Yann"
302 results on '"Touchefeu, Yann"'

2. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study

Author

M’Baloula, Jeannie, Tougeron, David, Boilève, Alice, Jeanbert, Elodie, Guimbaud, Rosine, Ben Abdelghani, Meher, Durand, Alice, Turpin, Anthony, Quesada, Stanislas, Blanc, Jean Frédéric, Artru, Pascal, Toullec, Clémence, Trouilloud, Isabelle, Pellat, Anna, Touchefeu, Yann, Pinot, Julien, Caroli-Bosc, François-Xavier, Taïeb, Julien, Doat, Solène, Bouché, Olivier, Védie, Anne Laure, de Mestier, Louis, and Muller, Marie

Published
2024
Full Text
View/download PDF

3. Clinical Management of Gastric Cancer Treatment Regimens

Author

Boilève, Juliette, Touchefeu, Yann, Matysiak-Budnik, Tamara, Ahmed, Rafi, Series Editor, Akira, Shizuo, Series Editor, Casadevall, Arturo, Series Editor, Galan, Jorge E., Series Editor, Garcia-Sastre, Adolfo, Series Editor, Rappuoli, Rino, Series Editor, Rodrigues, Marcio L, Series Editor, Weber, Olaf, Series Editor, and Backert, Steffen, editor

Published
2023
Full Text
View/download PDF

5. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial

Author

Féray, Cyrille, Campion, Loic, Mathurin, Philippe, Archambreaud, Isabelle, Mirabel, Xavier, Bronowicki, Jean Pierre, Rio, Emmanuel, Perret, Christophe, Mineur, Laurent, Oberti, Frédéric, Touchefeu, Yann, Gournay, Jérôme, Regnault, Hélène, Edeline, Julien, Rode, Agnès, Hillion, Patrick, Blanc, Jean Frédéric, Khac, Eric Nguyen, Azoulay, Daniel, Luciani, Alain, Preglisasco, Athena Galetto, Faurel-Paul, Elodie, Auble, Hélène, Mornex, Françoise, and Merle, Philippe

Published
2023
Full Text
View/download PDF

9. Case Report of Concomitant Diagnosis of Locally Advanced Intrahepatic Cholangiocarcinoma and Solitary Plasmacytoma of T11 Vertebra: Impact on Diagnostic and Clinical Management.

Author

Touchefeu, Yann, Barbaud, Matthieu, Prin-Felix, Laura, Samarut, Edouard, Jamet, Bastien, Ollivier, Luc, and Bouda, Damien

Subjects
*SECONDARY primary cancer, *COMORBIDITY, *LIVER cancer, *CHOLANGIOCARCINOMA, *BONE metastasis
Abstract

A solitary bone plasmacytoma is a rare tumor. Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma. We present the case of a 48-year-old female patient who consulted for recent back pain, with a final diagnosis of T10 solitary plasmacytoma and synchronous intrahepatic cholangiocarcinoma. Imaging suggested cholangiocarcinoma with bone metastasis. The patient underwent neurosurgical management with laminectomy, arthrodesis, and arthrectomy, with biopsies revealing monotypic kappa plasmacytic proliferation. Liver biopsies revealed an adenocarcinoma with expression of cytokeratin 19, cytokeratin 7, N-cadherin, and high expression of carbonic anydrase IX. The plasmacytoma was treated with external radiotherapy. The cholangiocarcinoma was treated with selective internal radiation therapy and concomitant systemic treatment with combinations of cisplatin and durvalumab, with capecitabine during radiotherapy, switched for gemcitabine after completion of irradiation. One year after initial management, imaging revealed a partial metabolic response of the intrahepatic cholangiocarcinoma, and a complete metabolic response of the plasmacytoma. This case illustrates the importance of not ignoring two primary tumors and the management of two concomitant treatments exploiting potential therapeutic synergies and limiting expected toxicities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?

Author

Boilève, Juliette, Guimas, Valentine, David, Arthur, Bailly, Clément, and Touchefeu, Yann

Subjects
IMMUNE checkpoint inhibitors, CLINICAL trials, PROGRESSION-free survival, OVERALL survival, PROGNOSIS, HEPATOCELLULAR carcinoma
Abstract

Hepatocellular carcinoma (HCC) is a disease with a poor prognosis, often diagnosed at an advanced stage. Therapeutic options have developed considerably in recent years, particularly with trans-arterial treatments. Systemic treatments have also evolved significantly, with the rise of immune checkpoint inhibitors (ICI) as first-line treatment for advanced HCC. The combination of loco-regional treatments and ICI is opening up new prospects and is the subject of numerous clinical trials. Recently, two global phase 3 trials investigating ICI-based adjuvant combinations have demonstrated improvements in recurrence-free survival or progression-free survival in patients treated with resection, ablation, or trans-arterial chemoembolization. However, mature data and overall survival results are still awaited but will be difficult to interpret. We are at the start of a new era of combinations of loco-regional treatments and immunotherapy. The identification of the best therapeutic strategies and predictive biomarkers is a crucial issue for future standards in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients

Author

Abba, Julio, Abboud, Karine, Alyami, Mohammad, Arvieux, Catherine, Averous, Gerlinde, Bakrin, Naoual, Balagué, Gisèle, Barrau, Vincent, Ben Rejeb, Houda, Bereder, Jean-Marc, Berton-Rigaud, Isabelle, Bibeau, Frédéric, Bonnefoy, Isabelle, Bouzard, Dominique, Bricault, Ivan, Brigand, Cécile, Carrère, Sébastien, de Chaisemartin, Cécile, Chassang, Madleen, Chevallier, Anne, Courvoisier, Thomas, Dartigues, Peggy, Dohan, Anthony, Dubreuil, Julien, Dumont, Frédéric, Eveno, Clarisse, Faruch-Bilfeld, Marie, Ferron, Gwenaël, Fontaine, Juliette, Fournier, Laure, Gagniere, Johan, Geffroy, Delphine, Ghouti, Laurent, Gilly, François-Noël, Gladieff, Laurence, Glehen, Olivier, Goéré, Diane, Guibal, Aymeric, Guilloit, Jean-Marc, Guyon, Frédéric, Heyd, Bruno, Hoeffel, Christine, Hordonneau, Constance, Isaac, Sylvie, Jourdan-Enfer, Peggy, Kaci, Rachid, Kianmanesh, Reza, Labbé-Devilliers, Catherine, Lacroix, Joëlle, Lelong, Bernard, Leroux-Broussier, Agnès, Lherm, Yoann, Lo Dico, Réa, Lorimier, Gérard, Malhaire, Caroline, Marchal, Frédéric, Mariani, Pascale, Mathiotte, Emilie, Meeus, Pierre, Mery, Eliane, Msika, Simon, Nadeau, Cédric, Ortega-Deballon, Pablo, Passot, Guillaume, Pellet, Olivier, Peyrat, Patrice, Pezet, Denis, Pirro, Nicolas, Pocard, Marc, Poizat, Flora, Porcheron, Jack, Poulet, Anaïs, Quenet, François, Rat, Patrick, Rousselot, Pierre, Rousset, Pascal, Senellart, Hélène, Serrano, Martine, Servois, Vincent, Sgabura, Olivia, Skanjeti, Andrea, Svrcek, Magali, Tetreau, Raphaël, Thibaudeau, Emilie, Touchefeu, Yann, Tuech, Jean-Jacques, Valmary-Degano, Séverine, Vaudoyer, Delphine, Velasco, Stéphane, Verriele-Beurrier, Véronique, Villeneuve, Laurent, Wernert, Romuald, Zinzindohoue, Franck, Delhorme, Jean-Baptiste, Ohayon, Jordan, Gouy, Sébastien, Genestie, Catherine, Gaichies, Léopold, Quenet, Francois, Morice, Philippe, and Honoré, Charles

Published
2020
Full Text
View/download PDF

14. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author

Moussata, Driffa, Grangé, Jean-Didier, Ratziu, Vlad, Khemissa-Akouz, Faiza, Regnault, Hélène, Dauvois, Barbara, Zarski, Jean-Pierre, Ollivier-Hourmand, Isabelle, Manfredi, Sylvain, Debette-Gratien, Marilyne, Gangloff, Alice, Fontanges, Thierry, Baron, Aurore, Bouattour, Mohamed, Vincent, Julie, Sieghart, Wolfgang, Maieron, Andreas, Peeters, Marc, Delwaide, Jean, Lasser, Luc, Berg, Thomas, Schultheiß, Michael, Zipprich, Alexander, Trojan, Joerg, Ehmer, Ursula, Luppi, Gabriele, Luca, Giovanni, Tamberi, Stefano, Amoroso, Domenico, Alabiso, Oscar, Buonadonna, Angela, Toniutto, Pierluigi, Tamburini, Emiliano, Cubillo, Antonio, Muñoz, Andrés, Guillén, Carmen, Sánchez, Gloria, Manzano, Hermini, Navarro, Victor, Ales, Inmaculada, Massuti, Bartomeu, Dank, Magdolna, Bodoky, György, Kahan, Zsuzsanna, Horváth, Zsolt, Gabrail, Nashat, Ozer, Howard, Galanopoulos, Christos, Hauke, Ralph, Raj, Moses, Harputluoglu, Hakan, Sevinc, Alper, Goker, Erdem, Coker, Ahmet, Yalcin, Suayib, Ali, Muhammet, Ata, Ozlem, Tugba, Ilkay, El Kassas, Mohammed, Abdel, Amr, Wakid, Imam, Shamaa, Sameh, El Lahlouby, Nasr, Kohail, Hanaa, Makarem, Jawad, Chehade, Issam, Farhat, Fadi, López, Carlos, Marín, Miguel, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, and Vasseur, Bérangère

Published
2019
Full Text
View/download PDF

23. Évaluation et impact -pronostique de la fonction hépatique des patients sous traitement systémique pour un carcinome hépatocellulaire avancé.

Author

Delhoume, Victoria, Khaldi, Marion, Salimon, Maëva, and Touchefeu, Yann

Subjects
HEPATOCELLULAR carcinoma, PROGNOSIS, IMMUNOTHERAPY
Abstract

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

25. Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

Author

Lugat, Alexandre, primary, Frampas, Éric, additional, Touchefeu, Yann, additional, Mirallié, Éric, additional, Bras, Maëlle Le, additional, Senellart, Hélène, additional, Rauscher, Aurore, additional, Fleury, Vincent, additional, Campion, Loïc, additional, Rohmer, Vincent, additional, Couturier, Olivier-François, additional, Lebtahi, Rachida, additional, Rouzet, François, additional, Ruszniewski, Philippe, additional, Kraeber-Bodéré, Françoise, additional, Bourgeois, Mickaël, additional, and Ansquer, Catherine, additional

Published
2023
Full Text
View/download PDF

26. Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

Author

Auvray Kuentz, Marie, primary, Hautefeuille, Vincent, additional, de Mestier, Louis, additional, Coutzac, Clélia, additional, Lecomte, Thierry, additional, Nardon, Victor, additional, Artru, Pascal, additional, Turpin, Anthony, additional, Drouillard, Antoine, additional, Malka, David, additional, Tran‐Minh, My‐Linh, additional, Trouilloud, Isabelle, additional, Lièvre, Astrid, additional, Williet, Nicolas, additional, Pernot, Simon, additional, Touchefeu, Yann, additional, Taieb, Julien, additional, Hammel, Pascal, additional, and Zaanan, Aziz, additional

Published
2023
Full Text
View/download PDF

30. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial

Author

Coutzac, Clélia, primary, Bibeau, Frederic, additional, Ben Abdelghani, Meher, additional, Aparicio, Thomas, additional, Cohen, Romain, additional, Coquan, Elodie, additional, Dubreuil, Olivier, additional, Evesque, Ludovic, additional, Ghiringhelli, François, additional, Kim, Stefano, additional, Lesourd, Samuel, additional, Neuzillet, Cindy, additional, Phelip, Jean-Marc, additional, Piessen, Guillaume, additional, Rochigneux, Philippe, additional, Samalin, Emmanuelle, additional, Soularue, Emilie, additional, Touchefeu, Yann, additional, Tougeron, David, additional, Zaanan, Aziz, additional, and de la Fouchardière, Christelle, additional

Published
2022
Full Text
View/download PDF

36. Transcatheter arterial chemoembolization (TACE) followed by conformal radiotherapy versus TACE alone for hepatocellular carcinoma: a western controlled trial

Author

Feray, Cyrille, primary, Campion, Loic, additional, Mabile-Archambeaud, Isabelle, additional, Mathurin, Philippe, additional, Mirabel, Xavier, additional, Rio, Emmanuel, additional, Bronowicki, Jean-Pierre, additional, Touchefeu, Yann, additional, Gournay, Jérôme, additional, Rode, Agnès, additional, Mornex, Francoise, additional, and Merle, Philippe, additional

Published
2022
Full Text
View/download PDF

37. Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer

Author

Randrian, Violaine, primary, Pernot, Simon, additional, Sionneau, Baptiste, additional, Smith, Denis, additional, Lim, Annie, additional, Touchefeu, Yann, additional, Gallois, Claire, additional, Turpin, Anthony, additional, Javed, Sahir, additional, Guimbaud, Rosine, additional, Rivera, Pascale, additional, Karoui, Mehdi, additional, Auclin, Edouard, additional, and Taieb, Julien, additional

Published
2022
Full Text
View/download PDF

40. Traitements locorégionaux du cholangiocarcinome intra-hépatique.

Author

Briot, Antoine, Guimas, Valentine, Le Gal, Antoine, Bailly, Clément, and Touchefeu, Yann

Subjects
EXTERNAL beam radiotherapy, ADJUVANT chemotherapy, LIVER tumors, SURGICAL excision, HEPATOCELLULAR carcinoma, RADIOTHERAPY
Abstract

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

42. Prospective Multicentric Assessment of 68 Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.

Author

Lugat, Alexandre, Frampas, Éric, Touchefeu, Yann, Mirallié, Éric, Bras, Maëlle Le, Senellart, Hélène, Rauscher, Aurore, Fleury, Vincent, Campion, Loïc, Rohmer, Vincent, Couturier, Olivier-François, Lebtahi, Rachida, Rouzet, François, Ruszniewski, Philippe, Kraeber-Bodéré, Françoise, Bourgeois, Mickaël, and Ansquer, Catherine

Subjects
PANCREATIC tumors, RESEARCH, DISEASE progression, PERITONEAL cancer, POSITRON emission tomography computed tomography, RADIOISOTOPES, MAGNETIC resonance imaging, CANCER relapse, GASTROINTESTINAL tumors, GALLIUM isotopes, CANCER patients, NEUROENDOCRINE tumors, SINGLE-photon emission computed tomography, BONE metastasis, SOMATOSTATIN, DESCRIPTIVE statistics, RESEARCH funding, COMPUTED tomography, SENSITIVITY & specificity (Statistics), LONGITUDINAL method, NEUROTRANSMITTER receptors
Abstract

Simple Summary: Determining the most sensitive imaging technique to evaluate neuroendocrine tumors spread may have an impact on therapeutic management. The aim of this multicentric study was to prospectively assess 68Ga-DOTANOC PET/CT sensitivity compared to the combination of multiphasic CT, somatostatin receptor scintigraphy and MRI to evaluate whether this imaging modality results in therapeutic modifications. We confirm in a homogenous population of 105 grade 1 or 2 gastroenteropancreatic neuroendocrine tumors the higher sensitivity of 68Ga-DOTANOC PET/CT in per-patient and per-region analysis, as well as in the detection of primary tumor and small lesions such as peritoneal carcinomatosis and bone lesions leading to an impact on therapeutic management of almost half of the patients. The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by 68Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas

Author

Goislard de Monsabert, Camille, primary, Touchefeu, Yann, additional, Guiu, Boris, additional, Campillo-Gimenez, Boris, additional, Farges, Olivier, additional, Tougeron, David, additional, Baumgaertner, Isabelle, additional, Ayav, Ahmet, additional, Beuzit, Luc, additional, Pracht, Marc, additional, Lièvre, Astrid, additional, Le Sourd, Samuel, additional, Boudjema, Karim, additional, Rolland, Yan, additional, Garin, Etienne, additional, Boucher, Eveline, additional, and Edeline, Julien, additional

Published
2021
Full Text
View/download PDF

45. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group

Author

Breton, Clémence, primary, Meyer, Antoine, additional, Malka, David, additional, Matias, Margarida, additional, De Baere, Thierry, additional, Hammel, Pascal, additional, Sa Cunha, Antonio, additional, Lucchese, Angelica, additional, Fuks, David, additional, Coriat, Romain, additional, Gallois, Claire, additional, Touchefeu, Yann, additional, Maillet, Marianne, additional, Trouilloud, Isabelle, additional, Rompteaux, Pierre, additional, Carbonnel, Franck, additional, and Soularue, Emilie, additional

Published
2021
Full Text
View/download PDF

46. Carcinome hépatocellulaire : identification des patients à risque et dépistage.

Author

Ben Yedder, Nour, Habès, Sarah, Koudougou, Carelle, Salimon, Maëva, and Touchefeu, Yann

Subjects
HEPATIC fibrosis, CIRRHOSIS of the liver, MEDICAL screening, OVERALL survival, HEPATOCELLULAR carcinoma
Abstract

Résumé: Le carcinome hépatocellulaire (CHC) se développe dans la majorité des cas sur un foie cirrhotique. Le dépistage du CHC permet un diagnostic plus précoce de CHC, un accès plus fréquent à des traitements à visée curative et une amélioration de la survie des patients. En France, le dépistage par échographie abdominale semestrielle est recommandé chez les patients cirrhotiques. Cependant, seulement 20 % des patients ont un diagnostic dans le cadre d'un programme de dépistage. En l'absence de dépistage, il peut s'agir de patients ayant une cirrhose connue mais non correctement suivie, ou de patients n'ayant pas de cirrhose ou de fibrose hépatique connue. Reconnaître les patients à risque de maladie chronique du foie et identifier la fibrose avancée chez ces patients sont des axes d'optimisation du dépistage du CHC. Hepatocellular carcinoma (HCC) develops in most cases in a cirrhotic liver. HCC screening allows for an earlier diagnosis of HCC, more frequent access to treatments with curative intents, and improved patient survival. In France, biannual abdominal ultrasound screening for HCC is recommended for cirrhotic patients. However, only 20% of patients are diagnosed with HCC in a screening program. In case of patients diagnosed outside a screening programm, it may be either because they have known cirrhosis but are not properly followed, or because they have no known cirrhosis or liver fibrosis. Recognizing patients at risk for chronic liver disease and identifying advanced fibrosis in these patients are areas for optimizing HCC screening. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology

Author

Galle, Peter R., primary, Kudo, Masatoshi, additional, Llovet, Josep M., additional, Finn, Richard S., additional, Karwal, Mark, additional, Pezet, Denis, additional, Kim, Tae‐You, additional, Yang, Tsai‐Sheng, additional, Lonardi, Sara, additional, Tomasek, Jiri, additional, Phelip, Jean‐Marc, additional, Touchefeu, Yann, additional, Koh, Su‐Jin, additional, Stirnimann, Guido, additional, Liang, Kun, additional, Ogburn, Kenyon D., additional, Wang, Chunxiao, additional, Abada, Paolo, additional, Widau, Ryan C., additional, and Zhu, Andrew X., additional

Published
2021
Full Text
View/download PDF

50. Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors

Author

Girot, Paul, primary, Baudin, Eric, additional, Senellart, Hélène, additional, Bouarioua, Nadia, additional, Hentic, Olivia, additional, Guimbaud, Rosine, additional, Walter, Thomas, additional, Ferru, Aurélie, additional, Roquin, Guillaume, additional, Cadiot, Guillaume, additional, Pracht, Marc, additional, Girot, Jean-Baptiste, additional, Malka, David, additional, Ducreux, Michel, additional, Bennouna, Jaafar, additional, Matysiak-Budnik, Tamara, additional, Hadoux, Julien, additional, and Touchefeu, Yann, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results